

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE pond to a collection of information unless it restains.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

of

Complete if Known **Application Number** 10/070,569 **Filing Date** March 8, 2002 First Named Inventor Takashi Muramatsu **Group Art Unit** Examiner Name SPO-116 **Attorney Docket Number** 

NON PATENT LITERATURE DOCUMENTS							
Examiner Initials*	irem (book magazine lolima), serial symbosium, catalog, etc.), date, pagets), volumenssue						
and	R1	ARIDOME, K., J. TSUTSUI, S. TAKAO, K. KADOMATSU, M. OZAWA, T. AIKOU, and T. MURAMATSU. "Increased midkine gene expression in human gastrointestinal cancers." <i>Jpn. J. Cancer Res.</i> July, 1995. 86: 655-661.					
1	GARVER, R.I., D.M. RADFORD, H. DONIS-KELLER, M.R. WICK, and P.G. MILNER. "Midkine and pleiotrophin expression in normal and malignant breast tissue." <i>Cancer.</i> September 1, 1994. 74(5): 1584-1590.						
	R3 IKEMATSU, S., A. YANO, K. ARIDOME, M. KIKUCHI, H. KUMAI, H. NAGANO, K. OKAMOTO, M. ODA, S SAKUMA, T. AIKOU, H. MURAMATSU, K. KADOMATSU, and T. MURAMATSU. "Serum midkine levels a increased in patients with various types of carcinomas." <i>Br. J. Cancer.</i> 2000. 83(6): 701-706.						
*	R4	carcinomas." Hepato-Gastroenterology. 1999. 46: 3189-3196.					
	R5	Oncology. 1999. 57: 253-257.					
V	R6	MURAMATSU, H., et al. "Enzyme-linked immunoassay for midkine, and its application to evaluation of midkine levels in developing mouse brain and sera from patients with hepatocellular carcinomas." J. Biochem. 1996. 119 1171-1175.					
V	TSUTSUI, J., K. KADOMATSU, S. MATSUBARA, A. NAKAGAWARA, M. HAMANOUE, S. TAKAO, H. SHIMAZU, Y. OHI, and T. MURAMATSU. "A new family of heparin-binding growth/differentiation factors: increased midkine expression in Wilms' tumor and other human carcinomas." <i>Cancer Res.</i> 1993. 53: 1281-1285.	,					
	R8						
	R9						
	R10	DECEIVED					
	R11	RECEIVED  DEC 1 1 2002					
	R12	TECH CENTER 1600/2000					
	R13	,					

Examiner Date 320252		 		
Signature Considered Considered	Examiner		110/	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.